tbuckley/cabot-search huggingface dataset:
POS1150 BONE MINERAL DENSITY AND TRABECULAR BONE SCORE IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: N. Grygorieva, G. Dubetska
Journal: Annals of the Rheumatic Diseases (2022)

Background Patients with systemic lupus erythematosus (SLE) have an increased risk of osteoporosis and low trauma fractures due to several important factors: the inflammatory disease itself, low vitamin D level, use of some disease-modifying anti-rheumatic drugs, glucocorticoids, etc. [1]. Bone mineral density (BMD) and trabecular bone score (TBS) measured by DXA are the important parameters of bone strength that evaluate the different aspects of bone architecture [1, 2]. Objectives The aim of the research was to determine BMD and TBS in women with SLE. Methods We have examined 150 females from 20 to 75 years old (average age – 51.1±11.6 years) which were divided into 2 groups: patients with SLE (n=50) and healthy women (n=100). The females did not differ in terms of age (51.4±10.8 and 50.4±13.2 years, respectively; p=0.60), height (163.8±15.4 and 163.6±6.6 cm, p=0.86), body mass (73.6±15.9 and 68.8±14.8 kg, p=0.09), and the duration of the postmenopausal period (8.9±6.9 and 9.6±8.1 years, p=0.81), but the age of menopause was significantly lower in patients with SLE (47.9±4.7 and 42.1±15.3 years, respectively, p&lt;0.05). The BMD was measured at the lumbar spine, femoral neck, proximal femur, and total body, by means of the “Prodigy” unit (CE Medical systems, model 8743, 2005). The TBS was evaluated using the installed TBS iNsight software for an X-ray densitometer (Med-Imaps, Pessac, France). Results The parameters of BMD were significantly lower in patients with SLE compared to the healthy women in all measured areas: in the total body (0.95±0.05 and 1.06±0.12 g/cm 2 , respectively; р=0.03), in the lumbar spine (0.87±0.13 and 0.96±0.17 g/cm 2 , р=0.02), femoral neck (0.68±0.11 and 0.75±0.14 g/cm 2 , р=0.03), proximal femur (0.83±0.10 and 0.92±0.16 g/cm 2 , р=0.02). In the patients with SLE TBS was significantly lower compared to the index in healthy women (1.28±0.11 and 1.33±0.12 un., р=0.02). Conclusion The parameters of BMD and TBS in women with SLE are significantly lower than in the healthy population. Our results emphasize the importance of combined BMD and TBS measurement in the evaluation of the different aspects of bone architecture for dynamic monitoring of bone health and risk of fracture in patients with SLE and timely start of osteoporosis treatment. References [1]Bultink I.E.M. (2011). Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care &amp; Research, 64(1), 2–8. doi:10.1002/acr.20568. [2]Ruaro B., Casabella A., Paolino S. et al.(2020). Trabecular Bone Score and Bone Quality in Systemic Lupus Erythematosus Patients. Frontiers in Medicine, 7. doi:10.3389/fmed.2020.574842. Disclosure of Interests None declared
Telomere length and brain aging: A systematic review and meta-analysis
Authors: Piyush Gampawar, Reinhold Schmidt, Helena Schmidt
Journal: Ageing Research Reviews (2022)

The current evidence on the association of leukocyte telomere length (LTL) with age-related structural and cognitive changes in the brain is mixed. Herein conforming to PRISMA 2020 guidelines, we performed a systematic review and meta-analysis using data from 27 observational studies in non-demented individuals. We used effect size and p-value based meta-analysis methods considering marked heterogeneity among studies. We found that the longer LTL was associated with higher brain volume (β = 0.43, 95%CI: 0.36-0.50%, p = 0.008, N = 1102) and with higher global cognition (β = 0.01; 95%CI: 0.00-0.02, p = 0.03, N = 19609) by effect size based meta-analysis and with brain volume, hippocampal volume, global cognition, cognitive domains of attention/speed as well as executive functions by p-value based meta-analysis. No significant association of LTL with brain white matter hyperintensities was detected. Furthermore, the evidence strongly suggests a subgroup-specific canonical effect of telomeres, notably in older individuals and females. In conclusion, we provide meta-analytic evidence on the beneficial effect of telomeres on brain structure as well as cognition and advocate for a beneficial subgroup-specific effect that warrants further attention.
AB1484 THE SIGNIFICANCE OF ANTI-DFS70 ANTIBODIES IN HEALTHY POPULATION AS A MARKER OF EXCLUSION OF SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES
Authors: Z. Verizhnikova, V. Rybakova, A. Avdeeva, T. Panafidina, A. Lila, E. Nasonov
Journal: Annals of the Rheumatic Diseases (2022)

Background The prevalence of anti-DFS70 antibodies in healthy volunteers (HV) by various methods ranges from 0 to 22% [1]. This pattern, which is rare in patients with systemic autoimmune rheumatic diseases (SARDs), has been described as the second most common in serum HV [2]. Objectives To study the frequency of detection of anti-DFS70 in HV, patients (pts) with undifferentiated SARDs and systemic lupus erythematosus (SLE). Methods A total of 45 HV, 17 undifferentiated SARDs pts and 81 SLE pts were included in the study. Groups were comparable in gender and age among themselves. The diagnosis of SLE was performed according to the ACR/EULAR 2019 classification criteria. Serum samples were tested for anti-DFS70 (ANA HEp-2 ELITE/DFS70 knock-out IFA, “Trinity Biotech”, Ireland). Fluorescence titers ≥1:160 were considered as positive for ANA HEp-2 cell patterns. Results Positive results of the ANA study were found in 81 (100.0%) pts with SLE, in 16 (94.0%) pts with undifferentiated SARDs and 7 (15.6%) HV (Table 1). Abs to DFS70 were isolated, detected in 4 (57.1%) HV, in 9 (56.2%) undifferentiated SARDs, but were not detected in SLE pts. Classical HEp-2 cell patterns (homogeneous AC-1, speckled AC-4.5, homogeneous+speckled AC-1,4,5, cytoplasmic AC-19,20,21) without anti-DFS70 were deficient in 3 (42.9%) HV, in 7 (43.8%) patients with undifferentiated SARDs and in 81 (100%) patients with SLE (Table 2). Therefore, monospecific anti-DFS70 were detected in the HV and undifferentiated SARDs groups, but were not detected in patients with a reliable diagnosis of SLE. Conclusion Monospecific anti-DFS70 can potentially be considered as a possible marker for the exclusion of SARDs and a sign of benign autoimmunity. References [1]Conrad K, Röber N, Andrade LEC, Mahler M. The Clinical Relevance of Anti-DFS70 Autoantibodies. Clinic Rev Allerg Immunol (2017) 52:202–216. [2]Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LEC (2011) Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 63:191–200. Disclosure of Interests None declared
AB0813 Correspondence between patient-reported flare and disease activity score variation in axial spondyloarthritis
Authors: F. Costantino, A. Leboime, L. Bessalah, M. Breban
Journal: Annals of the Rheumatic Diseases (2022)

Background There is currently no consensual definition of flare in axial spondyloarthritis (axSpA). Objectives The aims of this study were to determine thresholds of variations of BASDAI associated with patient-reported flare and to test performance of ASAS preliminary definitions of flare 1 . Methods This prospective study was proposed to all patients registered on the Spondy+ platform, a secure e-health platform for SpA patients. Every week during one year, patients were invited to connect to the platform to fill a BASDAI questionnaire, a 0-10 pain visual analogic scale and to answer to the following question: “has your disease flared up since last week?”. Variations of BASDAI and pain between connections were assessed and associated to the change of perception of flare. ROC curves were built to assess performances of BASDAI and VAS to identify patient-reported occurrence and resolution of flare. Performance of ASAS preliminary definitions of flare was also assessed. Results 99 patients participated to this study for an average duration of 309 ± 148 days. 92% of them reported at least one episode of flare over follow-up. Area under the ROC curve (AUC) was significantly higher for ΔBASDAI than for Δpain, to predict outbreak of flare (0.81 vs 0.77, p=0.02). In contrast, ΔBASDAI and Δpain were comparably accurate to predict flare resolution with no significant difference of AUC (0.78 vs 0.80, p=0.4). Best performance was obtained for an increase of 0.2 points of BASDAI (sensitivity=70%; specificity=79%) and 0.5 of pain VAS to predict outbreak of flare and a decrease of 0.4 points of BASDAI and 0.5 of pain VAS to predict flare resolution (Figure 1). None of the ASAS definitions yielded sensitivity values higher than 37% whereas specificity was higher than 95% for all of them. Figure 1. Sensitivity (red dots) and specificity (blue dots) according to ΔBASDAI (panels A,C) and Δpain (panels B,D) threshold as predictors of outbreak (panels A,B) or resolution (panels C,D) of flare. Conclusion ΔBASDAI appeared as a suitable variable to monitor both occurrence and resolution of SpA flare, as reported by patient. References [1]Gossec L et al. Ann Rheum Dis 2016; 75 :991–6. doi:10.1136/annrheumdis-2015-208593 Acknowledgements The authors thank MSD France for unrestricted financial support to the SPONDY+ platform and Frédéric Durand-Salmon for giving us the possibility to use SPONDY+, a patient support program developed by BEPATIENT. Disclosure of Interests None declared
POS1387 ULTRASOUND FINDINGS OF JOINTS AND ENTHESES FOLLOWING ONE HOUR OF AGE AND GENDER ADJUSTED WEIGHT TRAINING
Authors: J. K. Schreiner, F. Recker, D. Scheicht, P. Karakostas, J. Ziob, C. Behning, P. Preuss, P. Brossart, V. Schäfer
Journal: Annals of the Rheumatic Diseases (2022)

Background Joint effusion and enthesitis are common ultrasound findings in rheumatologic diseases like rheumatoid arthritis or spondyloarthritis. Physically active individuals and athletes were also found to exhibit structural and vascular changes in their entheses, as well as joint effusion through different imaging approaches [1, 2]. Objectives The aim of this study was to evaluate the development of joint and entheseal ultrasound findings in large and medium joints of young healthy individuals after one hour of standardised weight training. Methods A total of three musculoskeletal ultrasound examinations were performed in healthy individuals under the age of 30 years. The first examination was carried out before the individuals conducted one hour of standardized weight training, the second examination 24 hours later and the third examination 48 hours later. The examination comprised shoulder, elbow, wrist, hip, knee, and ankle joints, as well as associated entheseal sites. Poisson mixed effects models were applied to analyse the development of the ultrasound findings within 48 hours after the weight training. Results Fifty-one healthy individuals with a mean age of 23.7 years (± 2.5, range: 19-30) (52.9% female) were enrolled in this study. Fourteen participants (27.5%) presented with at least one abnormal enthesis at baseline, increasing to 24 (47.1%) after 24 hours and to 29 (56.9%) 48 hours after the weight training. Hyperperfusion was the only entheseal pathology detected by ultrasound after the training. The number of individuals with at least one joint effusion increased from 37 (72.6%) at baseline to 45 (88.2%) after 24 hours and to 48 (94.1%) 48 hours after the weight training. The Poisson mixed effects models showed a significant increase of the number of joints with effusion and entheses with pathologies with time after the weight training (p &lt; 0.001, Exp(b) = 1.63 and p &lt; 0.001, Exp(b) = 1.58). Conclusion Prevalence of joint effusion in large and medium joints as well as the prevalence of entheseal pathology increase significantly within 48 hours after one hour of weight training. As a result, the individual’s physical activity should be considered when performing a musculoskeletal ultrasound examination. References [1]Méric J-C, Grandgeorge Y, Lotito G, Pham T. Walking Before an Ultrasound Assessment Increases the Enthesis Score Significantly. J Rheumatol. 2011 May;38(5):961–961. [2]Lohman M, Kivisaari A, Vehmas T, Kallio P, Malmivaara A, Kivisaari L. MRI abnormalities of foot and ankle in asymptomatic, physically active individuals. Skeletal Radiol. 2001 Mar 5;30(2):61–6. Disclosure of Interests None declared
AB0839 EXTRA-ARTICULAR MANIFESTATIONS IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
Authors: K. Tahir, N. Akasbi, I. El Mezouar, T. Harzy
Journal: Annals of the Rheumatic Diseases (2022)

Background Spondyloarthritis (SpA) is a chronic inflammatory arthritis that combines joint involvement and extra-articular manifestations such as inflammatory bowel disease (IBD), uveitis and psoriasis. Objectives The aim of our study was to compare extra-articular manifestations in patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Methods A retrospective study was conducted in a single rheumatology hospital in Morocco, including patients diagnosed as having SpA according to ASAS criteria 2010, during a period of 9 years. The patients were classified as AS by the presence of radiographic sacroiliitis according to the modified New York criteria and nr-axSpA defined by the presence of sacroiliitis on MRI. Extra-articular manifestations are compared between the two groups Results 375 patients were analyzed. 206 were female (54,9%). The mean age were 46,8 ± 14 years [16-84]. The mean duration of disease progression were 13.38 ± 8.44 years. The mean BASDAI were 4.20 ± 1.60 and the mean BASFI were 4.40 ± 2.24. 68,5% of patients had AS and 31.5% patients had nr-axSpA. Extra-articular manifestations were found in 109 (29,1%) of the patients, 72 (19,2 %) had IBD, 49 (13,1%) had uveitis and 9 (2,4%) had psoriasis. In bivariate analysis, IBD was noted in 23 % of patients with AS versus 11 % of patients with nr-axSpA (p= 0.006), psoriasis was present in 3.5% of patients with AS (p = 0.040), uveitis was present in 15.6% of AS (p = 0.034). Conclusion Extra articular manifestations are frequent in SpA. They are more frequent in patient with AS. Physicians need to screen carefully for extra articular manifestations at diagnosis and over follow-up. Disclosure of Interests None declared
POS0769 CANCER DEVELOPMENT IN PATIENTS HOSPITALISED WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A LONGITUDINAL, POPULATION-LEVEL DATA LINKAGE STUDY
Authors: W. Raymond, D. Preen, H. Keen, C. Inderjeeth, J. Nossent
Journal: Annals of the Rheumatic Diseases (2022)

Background The association between systemic lupus erythematosus (SLE) and cancer risk is unclear. Objectives Describe the association between systemic lupus erythematosus (SLE) and the risk of cancer development and subsequent 5-year mortality in Western Australia (WA). Methods Population-level cohort study of SLE patients (n=2,111) and general population comparators (n=21,110) hospitalised between 1980–2014. SLE patients (identified by ICD-9-CM: 695.4, 710.0, and ICD-10-AM: L93.0, M32.0) were nearest matched (10:1) for age, sex, Aboriginality, and temporality. Follow-up was from timezero (index SLE hospitalisation) to cancer development, death or 31/12/2014. Using longitudinal linked health data, we determined the risk of cancer development and subsequent 5-year mortality between SLE patients and comparators with Cox proportional hazards regression models. Results SLE patients had similar multivariate-adjusted risk (aHR 1.03, 95%CI 0.93, 1.15; P=0.583) of cancer development. Cancer development risk was higher in SLE patients &lt;40 years old (aHR 1.51), and from 1980-1999 (aHR 1.28). SLE patients had higher risk of developing cancer of the oropharynx (aHR 2.13); vulvo-vagina (aHR 3.22); skin (aHR 1.20), and, lymphatic and haematopoietic tissues (aHR 1.78), all P&lt;0.05. SLE patients had reduced risk of breast cancer (aHR 0.64). After cancer development, SLE patients had increased risk of 5-year mortality (aHR 1.16, 95%CI 1.01, 1.33); highest in 40-49 years old (aHR 1.89), and in those with skin (aHR 1.65) or prostate cancer (aHR 4.74). Conclusion Hospitalised SLE patients had increased risk of multiple cancers, but a reduced risk of breast cancer. Following cancer development, SLE patients had increased risk of 5-year mortality. Together there is scope to improve cancer prevention and surveillance in SLE patients. Acknowledgements The authors wish to thank the staff at the Western Australian Data Linkage Branch and Emergency Department Data Collection, Hospital Morbidity Data Collection, Western Australian Cancer Registry, and Death Registrations. The authors wish to thank the Australian Co-ordinating Registry, the Registries of Births, Deaths and Marriages, the Coroners, the National Coronial Information System and the Victorian Department of Justice and Community Safety for enabling COD URF data to be used for this publication. Disclosure of Interests None declared
Advancing innovative clinical trials to efficiently deliver medicines to patients
Authors: Robert A. Beckman, Fanni Natanegara, Pritibha Singh, Freda Cooner, Zoran Antonijevic, Yi Liu, Cristiana Mayer, Karen Price, Rui Tang, Amy Xia, Maria Apostolaros, Courtney Granville, Debra Michaels
Journal: Nature Reviews Drug Discovery (2022)
POS0604 THE EFFECT OF TRANSCUTANEOUS AURICULAR VAGUS NERVE STIMULATION AND DEEP BREATHING EXERCISES ON HEART RATE VARIABILITY IN HEALTHY PARTICIPANTS AND PATIENTS WITH RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: M. K. Jensen, S. S. Andersen, C. H. Liboriussen, S. S. Andersen, M. R. Jochumsen, S. Kristensen
Journal: Annals of the Rheumatic Diseases (2022)

Background Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are chronic autoimmune diseases associated with a reduced function of the autonomic nervous system including an impaired function of the vagus nerve (VN). The VN has potential anti-inflammatory effects, which could be utilized in a new treatment approach using vagus nerve stimulation (VNS). Different types of VNS exist, but no direct comparison has been made of the methods in patients with RA and SLE. Objectives The aim of this study was to compare the effect of transcutaneous auricular VNS (taVNS) and deep breathing (DB) on vagal tone in patients with RA or SLE and healthy participants and to investigate the washout effect assessed through time domain heart rate variability (HRV) measures (RMSSD (root-mean-square of successive differences), SDNN (standard deviation of N-N intervals), and PNN50 (percentage of adjacent N-N intervals that differ from each other by more than 50 milliseconds)). Methods The study was designed as an open label cross-over study. 42 healthy participants and 52 patients with RA or SLE performed two interventions, 30 minutes of taVNS and 30 minutes of DB. The interventions were separated by at least 24 hours. Before each intervention, two 5-minutes ECG-recordings were made to determine the participants’ baseline HRV. After each intervention three 5-minutes ECG-recordings were conducted in the following 30 minutes to investigate the potential washout effect. Results Healthy participants: A significant increase in SDNN, RMSSD, and PNN50 were found after DB. SDNN increased significantly immediately after taVNS. SDNN was significantly higher after DB compared to taVNS. Otherwise, there were no significant differences between the effects of the two interventions. Patients: A significant increase in SDNN, RMSSD, and PNN50 were present after both DB and taVNS. No significant differences were found between the effects of the two interventions. The effects of the interventions were still measurable 30 minutes after intervention, indicating no washout. Conclusion DB causes the greatest increase in HRV for healthy participants, while both DB and taVNS can equally elevate HRV in patients with RA and SLE, which support their use as a potential new treatment approach. However, their clinical effect needs to be investigated in future studies. Acknowledgements The authors thank patients and research personnel at Aalborg University Hospital. Disclosure of Interests None declared
AB0817 COMORBIDITIES IN ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: ARE THERE ANY DIFFERENCES?
Authors: K. Tahir, N. Akasbi, I. El Mezouar, T. Harzy
Journal: Annals of the Rheumatic Diseases (2022)

Background While comorbidity is increasingly being recognized and examined within patients with Axial spondyloarthritis (axSpA), few studies have investigated the occurrence of comorbidities in patients with non-radiographic axial spondyloarthritis (nr-axSpA) in relation to ankylosing spondylitis (AS). Objectives The aims of our study were to compare characteristics, comorbidities and medications between AS and nr-axSpA patients and to compare comorbidities between the two groups. Methods A cross-sectional study was conducted in a single rheumatology hospital in Morocco, including patients diagnosed as having axSpA according to ASAS criteria 2010, during a period of 9 years. The comorbidities studied were hypertension, diabetes, dyslipidemia, cardiac, digestive and pulmonary disorders, osteoporosis, renal insufficiency and neoplastic pathologies. Demographic, clinical, laboratory, comorbidities and treatment data were compared between AS and the nr-axSpA subgroups. Results 375 patients were included in the study. The cohort was predominantly female (54,9%) with a mean age of 46,83 years (± 14,00). 129 (50,2%) had at least one comorbidity. The mean number of comorbidities was 0,8 (± 1,05). We compared 257 AS to 118 with nr-axSpA. AS patients were significantly young (45 vs 50 years; p=0,0001), more frequently male (55% vs 22%; p=0001) and had higher serum inflammatory markers than those with nr-axSpA. The mean number of comorbidities was similar between AS and nr-axSpA groups. 31,1% of patients SA have a history of biologics DMARD-use (p=0,046) and less use NSAID (89,5 % vs 96,6 %; p=0,02). There were no statistically significant differences in prevalence of comorbidities between AS and nr-axSpA groups except hypertension which was higher in nr-SpA patients (24,6% vs. 14,4%, p=0,016) and digestive disorders which was most frequently detected in patients with AS (12,5 % vs 5,9%, p=0,05). The prevalence of cardiac disorders (p =0,068) and diabetes (p = 0,09) was nearly statistically significant. The multivariate analysis showed that hypertension is associated to AS form (OR: 1,976; IC [1,088-3,589]) Conclusion Comorbidities were common in both axSpA populations with small differences between AS and nr-axSpA. These results highlight the importance of identifying and managing comorbidities. Disclosure of Interests None declared